Epygenix clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.
- Notable: ARGUS · EPX-100 (Clemizole Hydrochloride) · Dravet Syndrome Primary endpoint(s) modified
- Minor: Clemizole HCl · Lennox-Gastaut Syndrome Trial sites expanded: 61 → 71 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-16 | NCT07879170 A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants | Phase 1 | Recruiting |
Active trials by phase
| Phase 1 | 1 | |
| Phase 3 | 2 |
Disease areas by active trials
Epilepsy (2)
Get alerts when Epygenix's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.